Emergent virus

Top Virologists to Meet in Monaco to Tackle Ongoing Pandemic Challenges and Emerging Viral Threats

Retrieved on: 
Wednesday, October 11, 2023

This coalition of the world’s leading medical virology researchers, who work together to prevent illness and death from viral disease, will hold high-level scientific sessions examining pandemic preparedness and current threats.

Key Points: 
  • This coalition of the world’s leading medical virology researchers, who work together to prevent illness and death from viral disease, will hold high-level scientific sessions examining pandemic preparedness and current threats.
  • A special GVN-CSM joint session will focus specifically on preparedness in European Union countries and will be attended by the High Patronage of H.S.H.
  • Prince Albert II of Monaco, among other dignitaries.
  • Lander Professor of Public Health, Yale School of Public Health as its next GVN President, effective November 1, 2023.

CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment

Retrieved on: 
Tuesday, September 19, 2023

Europe has the highest burden of liver disease in the world and cases are expected to grow across many countries.

Key Points: 
  • Europe has the highest burden of liver disease in the world and cases are expected to grow across many countries.
  • Safety data in people with severe hepatic impairment are limited and there are few treatment options that are safe and effective.
  • This positive opinion was based on results from a Phase 1 study of safety and pharmacokinetics in people with hepatic impairment (GS-US-540-9014).
  • “Expanding the use of Veklury to those with hepatic impairment will help more people gain access to treatment for COVID-19.”
    This positive opinion follows recent approvals in the U.S. and the EU which extended the approval of Veklury to treat COVID-19 in people with renal and hepatic impairment.

FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis

Retrieved on: 
Friday, July 14, 2023

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury® (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury® (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis.
  • With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease.
  • “Patients with advanced CKD and end-stage kidney disease (ESKD) are at high risk for severe COVID-19 with hospitalization and mortality rates remaining high, even for those who are vaccinated.
  • Veklury is contraindicated in patients who are allergic to Veklury or any of its components; please see below for additional Important Safety Information for Veklury.

CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis

Retrieved on: 
Friday, May 26, 2023

The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that can be used across all stages of renal disease.

Key Points: 
  • The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that can be used across all stages of renal disease.
  • In Europe, approximately 75 million people suffer from chronic kidney disease (CKD).
  • Patients with advanced CKD or end stage kidney disease (ESKD) represent a population that is highly vulnerable to COVID-19.
  • “Gilead’s commitment to address the unmet needs of the most susceptible populations remains a top priority.

Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks

Retrieved on: 
Thursday, June 23, 2022

Together, these data reinforce the clinical utility of bulevirtide as monotherapy for the treatment of chronic HDV.

Key Points: 
  • Together, these data reinforce the clinical utility of bulevirtide as monotherapy for the treatment of chronic HDV.
  • There are currently no other approved treatment options for HDV and people living with HDV typically have a poor prognosis.
  • Combined response was defined as undetectable HDV RNA or a decrease by 2 log10 IU/mL from baseline and ALT normalization.
  • Participants treated with bulevirtide 2 mg (n=49) showed significant improvements from baseline at 48 weeks in almost all assessed health-related quality-of-life domains of the Hepatitis Quality of Life questionnaire.

Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022

Retrieved on: 
Friday, February 11, 2022

This data will be presented at the 29th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2022) taking place from February 12-16.

Key Points: 
  • This data will be presented at the 29th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2022) taking place from February 12-16.
  • These latest data demonstrate that Veklury was generally well tolerated among pediatric patients hospitalized with COVID-19 with a high proportion of participants showing clinical improvement and recovery.
  • Of the 53 pediatric patients enrolled in the study, no new safety signals were apparent for Veklury.
  • Please see below for more information on the approved use of Veklury and the EUA for pediatric patients.

Legrand Announces Publication of Research Study Demonstrating Indigo-Clean Light Technology Effectively and Safely Kills SARS-CoV-2 and Influenza A Viruses

Retrieved on: 
Thursday, September 30, 2021

KENOSHA, Wis., Sept. 30, 2021 /PRNewswire/ -- Legrand today announced the publication of research showing its IndigoClean light disinfection technology effectively and safely inactivates SARS-CoV-2 and influenza A viruses in a range of real-world clinical settings.

Key Points: 
  • KENOSHA, Wis., Sept. 30, 2021 /PRNewswire/ -- Legrand today announced the publication of research showing its IndigoClean light disinfection technology effectively and safely inactivates SARS-CoV-2 and influenza A viruses in a range of real-world clinical settings.
  • The paper, "The virucidal effects of 405 nm visible light on SARS-CoV-2 and influenza A virus,"was published in Scientific Reports on September 30, 2021.
  • It reflects how researchers evaluated the inactivation rate of the SARS-CoV-2 virus using 405 nm visible light under a range of clinical conditions.
  • Longer wavelengths with less irradiation energy such as visible light (405 nanometers) have largely been evaluated in bactericidal and fungicidal applications.

Physician-Scientist Steven Quay and an International Team of Scientists and Investigators Provide Science-Based Analysis of the Origin of COVID-19 to the US Congress

Retrieved on: 
Thursday, July 15, 2021

Unlike with previous natural zoonotic epidemics, there was no evidence of pre-pandemic animal-to-human transmission and no evidence of an intermediate animal host.

Key Points: 
  • Unlike with previous natural zoonotic epidemics, there was no evidence of pre-pandemic animal-to-human transmission and no evidence of an intermediate animal host.
  • "A research-related accident involves a single transmission of a pure virus to one human and then human-to-human spread," said Dr. Quay.
  • Dr. Steven Quay has 360+ published contributions to medicine and has been cited over 10,000 times, placing him in the top 1% of scientists worldwide.
  • He is the author of the best-selling book on surviving the pandemic, Stay Safe: A Physician's Guide to Survive Coronavirus.

Animal Growth Enhancers Market| New Opportunities | Protection of Humans from Animal-food Related Diseases to Boost Growth in the Health Care Industry | Technavio

Retrieved on: 
Friday, May 7, 2021

The growing need to protect humans from animal-food-related diseases will be one of the significant factors that will have a positive impact on the market's growth.

Key Points: 
  • The growing need to protect humans from animal-food-related diseases will be one of the significant factors that will have a positive impact on the market's growth.
  • The administration of anti-microbial agents in animals helps to control the transmission of diseases such as zoonotic pathogens from animals to humans.
  • China,India, and Indonesia are the key markets for the animal growth enhancers market in Asia.
  • Market growth in this region will be fasterthan the growth of the market in other regions.

Prominent Australian and Russian Research Institutions Join Global Virus Network to Combat Viral Diseases

Retrieved on: 
Wednesday, September 9, 2020

The two new institutions bring GVN's total number of Centers of Excellence to 57, along with 10 affiliates in 33 countries.

Key Points: 
  • The two new institutions bring GVN's total number of Centers of Excellence to 57, along with 10 affiliates in 33 countries.
  • "EVIT will strengthen our depth and collaborative network in arbovirology, particularly in the Asia-Pacific region, Southeast Asia, India, South America and South Africa.
  • The Chumakov Center has unique expertise in varying areas of virology with many global connections, making it Russia's leading research organization in the field of virology."
  • Additionally, EVIT focuses on emerging viruses such as Hendra and SARS-CoV-2, and established viruses such as influenza virus and respiratory syncytial virus.